Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05102552




Registration number
NCT05102552
Ethics application status
Date submitted
22/09/2021
Date registered
1/11/2021
Date last updated
30/08/2022

Titles & IDs
Public title
Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects
Scientific title
A Single-Center, Randomized, Open-label, Multiple-Dose, Single-Sequence Crossover Study, Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects
Secondary ID [1] 0 0
817P106
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy Volunteer 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - SPN-817, Treatment B
Treatment: Drugs - SPN-817, Treatment C
Treatment: Drugs - BIS-001, Treatment A

Active comparator: Cohort 1 - BIS-001: Treatment A and SPN-817: Treatment B

Active comparator: Cohort 2 - BIS-001: Treatment A and SPN-817: Treatment C


Treatment: Drugs: SPN-817, Treatment B
SPN-817 Treatment B, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor

Treatment: Drugs: SPN-817, Treatment C
SPN-817 Treatment C, is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor

Treatment: Drugs: BIS-001, Treatment A
BIS-001 is an Extended Release formulation of Huperzine A, an acetylcholinesterase inhibitor
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Relative Bioavailability
Timepoint [1] 0 0
22 days
Primary outcome [2] 0 0
Relative Bioavailability
Timepoint [2] 0 0
22 days
Secondary outcome [1] 0 0
To assess the safety and tolerability of multiple oral administration of SPN-817 in healthy adult subjects.
Timepoint [1] 0 0
25 days

Eligibility
Key inclusion criteria
Inclusion Criteria

1. Healthy adult male or female volunteers, 18-55 years of age inclusive.
2. Weight of at least 50 kg and within the normal Body Mass Index (BMI) between 18 - 32 kg/m2 (inclusive).
3. Considered medically healthy by the Investigator via assessment of physical and neurological examinations, medical history, clinical laboratory tests, vital signs, and electrocardiogram (ECG)
4. Able and willing to swallow whole capsules and capsule contents without breaking, cutting, or chewing.
5. Able to voluntarily provide written informed consent to participate in the study.
6. Post-menopausal females with amenorrhea for at least 12 months with a serum follicle stimulating hormone [FSH] level of >40 IU/L) or women of non-childbearing potential (WONCBP) who are permanently sterilized (bilateral tubal ligation, hysterectomy, bilateral oophorectomy for six months minimum prior to screening).
7. Non-pregnant females of childbearing potential who are either sexually inactive (abstinent) or, if sexually active with a male partner who is biologically capable of having children, agree to use one of the following acceptable birth control methods beginning 14 days prior to the first dose, throughout the study, and for 30 days following the last dose:

* Hormonal contraceptive (i.e., oral, transdermal/subdermal; implant or injection)
* Intrauterine device (IUD)
* Double contraceptive methods (e.g. oral contraception and condom)
* Vasectomized partner (6 months minimum)
8. Male subjects who are biologically capable of having children (i.e., non-vasectomized) who are sexually inactive (abstinent) or, if sexually active with a female of childbearing potential, must agree to use one or more of the above forms of birth control for themselves and their partner(s), as appropriate, beginning 14 days prior to the first dose through at least 90 days following the last administration of study drug. They must also agree to abstain from sperm donation from the first administration of study drug to 90 days after the last administration of study drug.
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Exclusion Criteria

1. History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease.
2. Evidence of suicidality (defined as either active suicidal plan/intent or active suicidal thoughts, or more than one lifetime suicide attempt) within six months before Screening, or at Screening and Day -1 as determined by C-SSRS.
3. Evidence of infection with Hepatitis B or C, or human immunodeficiency virus HIV-1 or HIV2, as determined by results of testing at screening.
4. Positive urine drug screen (for amphetamines, methamphetamines, methadone, barbiturates, benzodiazepines, cocaine, opiates, methylenedioxymethamphetamine, tetrahydrocannabinol and phencyclidine) at Screening and at Day -1.
5. Clinically significant cardiology abnormalities at Screening and Day -1.

* Abnormal ECG that is, in the investigator's opinion, clinically significant including heart rate <50 BPM (average of 3);
* PR interval > 220 ms;
* QRS interval = 120 ms;
* QTcF interval > 450 ms (QT corrected using Fridericia's method);
* Second or third-degree atrioventricular block;
* Any rhythm, other than sinus rhythm, that is interpreted by the investigator to be clinically significant.
6. Creatinine clearance < 80 mL/min, according to the Cockcroft-Gault equation at Screening or Day -1.
7. Clinically significant vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate [HR] less than 50 or over 100 bpm) at Screening or check-in on Day -1.
8. History of intellectual disability (intellectual developmental disorder) or mental retardation.
9. A history of neuroleptic malignant syndrome.
10. A history of cancer within 5 years prior to screening or between screening and randomization (with the exception of non-metastatic basal and/or squamous cell carcinoma of the skin), any history of renal cell carcinoma or breast cancer, or a family history of lymphangioleiomyomatosis in association with tuberous sclerosis complex (TSC-LAM).
11. A history of clinically significant head trauma, including closed head injury with loss of consciousness.
12. A history of seizure, loss of consciousness for an unknown reason, or any other known neurological disorder placing the subject at risk for seizures.
13. History of significant alcohol abuse or drug abuse within one year prior to screening.
14. Regular use of alcohol within six months prior to Screening (more than 14 units of alcohol per week [1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]) or positive alcohol breath test at Screening or Day -1.
15. Use of drugs of abuse (such as cocaine, phencyclidine, amphetamines, methamphetamines, methadone, barbiturates, benzodiazepines, cocaine, opiates, methylenedioxymethamphetamine, tetrahydrocannabinol and phencyclidine ) within one year prior to Screening, or positive urine drug screen (for amphetamines, methamphetamines, methadone, barbiturates, benzodiazepines, cocaine, opiates, methylenedioxymethamphetamine, tetrahydrocannabinol and phencyclidine) at Screening or Day -1.
16. History of an allergic reaction to investigational product or related drugs, such as those with similar mechanism of action.
17. History of previous exposure to investigational product in a clinical trial.
18. Female subjects who are pregnant or lactating.
19. Use of prescription medication within 14 days prior to administration of study drug, or over-the-counter products (including natural food supplements) within seven days prior to administration of study drug. Exceptions include topical products without systemic absorption, hormonal contraceptives, hormone replacement therapy (stable dose for at least 30 days), and acetaminophen (2 g/day).
20. Any food allergy, intolerance, restriction, or special diet that, in the opinion of the Investigator, could contraindicate the subject's participation in this study.
21. History of anaphylaxis or severe allergy to any drug, food, toxin, or other exposure.
22. Subjects who received any investigational drug, device or biologic within 3 months or 5 half-lives (whichever is longer) of Day 1 dosing of study drug.
23. Subjects who have had the following blood or plasma donation:

* Subjects who donated 50 to 499mL of blood within 30 days and more than 499mL within 56 days prior to the first dose or have hemoglobin <128 g/L (males) or <115 g/L (females) and hematocrit <0.37 L/L (males) or <0.32 L/L (females) at Screening.
* Subjects who have had donated plasma within 7 days prior to dosing
24. Tobacco use as indicated by > 5 cigarettes per week or the equivalent, 30 days prior to Day -1.
25. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.

Study design
Purpose of the study
Other
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Phase 0
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
19/10/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
15/08/2022
Sample size
Target
Accrual to date
Final
30
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Nucleus Network - Melbourne
Recruitment postcode(s) [1] 0 0
3004 - Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Supernus Pharmaceuticals, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Randomized, Open-Label, Multiple Dose study to evaluate the relative bioavailability of Treatment A, Treatment B, and Treatment C
Trial website
https://clinicaltrials.gov/study/NCT05102552
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Jeanelle Portelli, Ph.D.
Address 0 0
Supernus Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05102552